Z

Zomedica Corp
AMEX:ZOM

Watchlist Manager
Zomedica Corp
AMEX:ZOM
Watchlist
Price: 0.13 USD -0.76% Market Closed
Market Cap: 127.4m USD
Have any thoughts about
Zomedica Corp?
Write Note

Zomedica Corp
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zomedica Corp
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zomedica Corp
AMEX:ZOM
Income from Continuing Operations
-$62.2m
CAGR 3-Years
-48%
CAGR 5-Years
-20%
CAGR 10-Years
-92%
Becton Dickinson and Co
NYSE:BDX
Income from Continuing Operations
$1.7B
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
4%
Boston Scientific Corp
NYSE:BSX
Income from Continuing Operations
$1.8B
CAGR 3-Years
16%
CAGR 5-Years
12%
CAGR 10-Years
20%
Stryker Corp
NYSE:SYK
Income from Continuing Operations
$3.6B
CAGR 3-Years
24%
CAGR 5-Years
14%
CAGR 10-Years
19%
Abbott Laboratories
NYSE:ABT
Income from Continuing Operations
$5.8B
CAGR 3-Years
-7%
CAGR 5-Years
12%
CAGR 10-Years
14%
Intuitive Surgical Inc
NASDAQ:ISRG
Income from Continuing Operations
$2.3B
CAGR 3-Years
10%
CAGR 5-Years
12%
CAGR 10-Years
18%
No Stocks Found

Zomedica Corp
Glance View

Market Cap
127.4m USD
Industry
Health Care

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company is headquartered in Ann Arbor, Michigan and currently employs 85 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's Diagnostics segment consists of TRUFORMA products. Its Therapeutics segment consists of PulseVet and Assisi products. Its TRUFORMA Bulk Acoustic Wave (BAW) point-of-care diagnostic platform is marketed with full diagnostic and thyroid panels for dogs and cats that include the only assays of these types available at the point of care to test for feline optimized TSH, endogenous ACTH, Free T4, and quantitative cortisol, along with a total T4 assay. The VetGuardian is its zero-touch vital signs remote monitoring system that enables contact-free, continuous monitoring of a pet's vital signs. The PulseVet is its electrohydraulic shockwave therapy platform. Its Assisi Loop line of products treats pain and inflammation through the delivery of targeted pulsed electromagnetic field focused energy (tPEMF).

ZOM Intrinsic Value
0.13 USD
Overvaluation 3%
Intrinsic Value
Price
Z

See Also

What is Zomedica Corp's Income from Continuing Operations?
Income from Continuing Operations
-62.2m USD

Based on the financial report for Sep 30, 2024, Zomedica Corp's Income from Continuing Operations amounts to -62.2m USD.

What is Zomedica Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-92%

Over the last year, the Income from Continuing Operations growth was -316%. The average annual Income from Continuing Operations growth rates for Zomedica Corp have been -48% over the past three years , -20% over the past five years , and -92% over the past ten years .

Back to Top